Literature DB >> 3385643

Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding.

D R Jones1, S D Hall, E K Jackson, R A Branch, G R Wilkinson.   

Abstract

The rapid intracarotid injection technique was used to determine the unidirectional brain uptake of a number of benzodiazepines in the rat. The drugs varied considerably in their lipophilicity and, within the series oxazepam, lorazepam, chlordiazepoxide, desmethyldiazepam and diazepam, brain extraction of unbound moiety was enhanced as the octanol-water (pH = 7.4) partition coefficient increased. However, with flunitrazepam and midazolam, two fluorine-containing benzodiazepines, extraction was more and less extensive, respectively, than predicted from their lipophilicities. Importantly, the uptake findings were consistent with the characteristic onsets of central effects of the drugs established clinically in humans. The effects of reversible protein binding on uptake also were investigated by the addition of albumin (0-8 g.dl-1) to the injectate. This affected markedly the unbound fraction, determined in vitro by equilibrium dialysis, and also the brain uptake of all drugs. As the unbound fraction was reduced, the unidirectional brain extraction ratio decreased in a curvilinear fashion toward zero. However, attempts to describe the data were unsuccessful using a conventional model based on transcapillary uptake of only unbound drug whose binding kinetics with albumin were assumed to be the same as those indicated by equilibrium dialysis. The observed brain extraction was greater than predicted, and the discrepancy became more apparent as binding and albumin concentration increased. The data for all of the benzodiazepines could be fitted, however, if the equilibrium association constant was assumed to be smaller in vivo than in vitro, so that the effective unbound fraction in the brain capillaries was substantially higher (5- to 25-fold, dependent on the particular drug) than that estimated in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3385643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

Review 2.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

3.  Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.

Authors:  A Hoffman; Y Lomnicky; M H Luria; D Gilhar; M Friedman
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

4.  Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.

Authors:  V P Gerskowitch; J Hodge; R A D Hull; N P Shankley; S B Kalindjian; J McEwen; J W Black
Journal:  Br J Clin Pharmacol       Date:  2006-10-17       Impact factor: 4.335

5.  A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations.

Authors:  Timothy S Carpenter; Daniel A Kirshner; Edmond Y Lau; Sergio E Wong; Jerome P Nilmeier; Felice C Lightstone
Journal:  Biophys J       Date:  2014-08-05       Impact factor: 4.033

Review 6.  Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures.

Authors:  Heather Ravvin McKee; Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

7.  Computational pharmacokinetic rationale for intra-arterial delivery to the brain.

Authors:  Johann N R Cooke; Jason A Ellis; Shaolie Hossain; Juliane Nguyen; Jeffrey N Bruce; Shailendra Joshi
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

8.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

Authors:  R K Dubey; C B McAllister; M Inoue; G R Wilkinson
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

Review 9.  Biological barriers, and the influence of protein binding on the passage of drugs across them.

Authors:  Karolina Wanat
Journal:  Mol Biol Rep       Date:  2020-03-05       Impact factor: 2.316

10.  Subjective and behavioral effects of diazepam depend on its rate of onset.

Authors:  H de Wit; S Dudish; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.